| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 9193- | ITCs, | PEITC, | BITC, | SFN, | Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research |
| - | Review, | Var, | NA |
| 8034- | IVM, | doxoR, | Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation |
| - | in-vitro, | Oral, | NA |
| 8033- | IVM, | dietMet, | rMETase, | Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 8022- | IVM, | Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage |
| - | vitro+vivo, | RCC, | NA |
| 8021- | IVM, | The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells |
| - | vitro+vivo, | AML, | HL-60 | - | NA, | lymphoma, | U937 | - | NA, | Pca, | DU145 |
| 8020- | IVM, | Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 8046- | IVM, | Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress |
| - | in-vitro, | CML, | NA |
| - | in-vitro, | Lung, | A549 |
| 8052- | IVM, | rMETase, | Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | Hs27 |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 8002- | JG, | Identification and Biological Evaluation of Juglone-Derived STAT3 Inhibitors against Colorectal Cancer |
| - | in-vitro, | PC, | NA | - | in-vitro, | CRC, | NA |
| 1917- | JG, | Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion |
| - | in-vitro, | AML, | HL-60 |
| 8090- | KAE, | A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound |
| - | Review, | Nor, | NA |
| 8095- | KAE, | Kaempferol: A Key Emphasis to Its Anticancer Potential |
| - | Review, | Var, | NA |
| 8102- | KAE, | Kaempferol inhibits gastric cancer tumor growth: An in vitro and in vivo study |
| - | vitro+vivo, | GC, | MKN-28 | - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | GC, | GES-1 |
| 8063- | KAE, | Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways |
| - | in-vitro, | Ovarian, | NA |
| 8065- | KAE, | Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HCT116 |
| 8066- | KAE, | Rad, | Radiosensitization of non-small cell lung cancer by kaempferol |
| - | in-vivo, | Lung, | A549 |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 8114- | LA, | Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate |
| - | in-vitro, | Cerv, | HeLa |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8249- | LCA, | Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells |
| - | in-vitro, | NSCLC, | NA |
| 8248- | LCA, | Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H460 |
| 8238- | LCA, | Licochalcone A is a Natural Selective Inhibitor of Arginine Methyltransferase 6 |
| - | in-vitro, | BC, | MCF7 | - | in-vivo, | NA, | MCF10 |
| 8206- | LCA, | Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways |
| - | in-vivo, | GC, | BGC-823 |
| 8233- | LCA, | Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer |
| - | in-vitro, | Lung, | NA |
| - | in-vitro, | Oral, | NA |
| 8287- | LE, | New insights into the antioxidant and apoptotic potential of Glycyrrhiza glabra L. during hydrogen peroxide mediated oxidative stress: An in vitro and in silico evaluation |
| - | in-vitro, | Nor, | NA |
| 8279- | LE, | 18β-Glycyrrhetinic Acid Has Anti-Cancer Effects via Inducing Apoptosis and G2/M Cell Cycle Arrest, and Inhibiting Migration of A549 Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H460 |
| 8130- | LF, | Lactoferrin targeting INTL1 receptor inhibits hepatocellular carcinoma progression via apoptosis and cell cycle signaling pathways |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HepG3 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8131- | LF, | Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma |
| - | in-vitro, | OS, | HSC2 | - | in-vitro, | OS, | HSC3 | - | in-vitro, | OS, | HSC4 | - | in-vitro, | Nor, | RT7 |
| 8132- | LF, | Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal V-H+-ATPase |
| - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MCF10 |
| 8134- | LF, | Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways |
| - | in-vitro, | CRC, | HT-29 |
| 8193- | LGE, | Targets and pathways involved in the antitumor activity of citral and its stereo-isomers |
| - | Review, | Var, | NA |
| 8191- | LGE, | Lemongrass (Cymbopogon citratus (D.C.) Stapf) Presents Antitumoral Effect and Improves Chemotherapy Activity in Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 8189- | LGE, | Lemongrass Extract Possesses Potent Anticancer Activity Against Human Colon Cancers, Inhibits Tumorigenesis, Enhances Efficacy of FOLFOX, and Reduces Its Adverse Effects |
| - | vitro+vivo, | CRC, | NA |
| 8184- | LGE, | Cytotoxicity of citral against melanoma cells: The involvement of oxidative stress generation and cell growth protein reduction |
| - | in-vitro, | Melanoma, | B16-BL6 | - | in-vitro, | Nor, | HaCaT |
| 8183- | LGE, | Antiproliferative and apoptosis inducing effects of citral via p53 and ROS-induced mitochondrial-mediated apoptosis in human colorectal HCT116 and HT29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 8333- | LIN, | Linalool preferentially induces robust apoptosis of a variety of leukemia cells via upregulating p53 and cyclin-dependent kinase inhibitors |
| - | in-vitro, | AML, | NA |
| 8331- | LIN, | Antitumorigenic potential of linalool is accompanied by modulation of oxidative stress: an in vivo study in sarcoma-180 solid tumor model |
| - | in-vivo, | sarcoma, | S180 |
| 8328- | LIN, | Linalool inhibits the growth of human T cell acute lymphoblastic leukemia cells with involvement of the MAPK signaling pathway |
| - | in-vitro, | AML, | NA |
| - | in-vitro, | Oral, | OECM-1 | - | in-vitro, | Nor, | FR-2 |
| 6464- | LIN, | 1,8-Cin, | Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Nor, | WI38 |
| 6479- | LIN, | Anticancer effect of linalool via cancer-specific hydroxyl radical generation in human colon cancer |
| - | in-vivo, | Colon, | HCT116 |
| 8392- | LT, | Revisiting Luteolin Against the Mediators of Human Metastatic Colorectal Carcinoma: A Biomolecular Approach |
| - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Nor, | RWPE-1 |
| 8403- | LT, | Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 2925- | LT, | Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3 |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | BC, | MCF7 |
| 2904- | LT, | Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons |
| - | in-vitro, | Park, | SK-N-SH | - | in-vitro, | AD, | NA |
| 8345- | Lut, | Lutein inhibits breast cancer cell growth by suppressing antioxidant and cell survival signals and induces apoptosis |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8347- | Lut, | Carotenoid Lutein Selectively Inhibits Breast Cancer Cell Growth and Potentiates the Effect of Chemotherapeutic Agents through ROS-Mediated Mechanisms |
| - | in-vitro, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid